Evaluation of antigen-specific immunoglobulin G responses in pulmonary tuberculosis patients and contacts

Yun-Gyoung Hur, a Ahreum Kim, a Young Ae Kang, b An Sik Kim, c Dae Yeon Kim, c Yeun Kim, d Youngmi Kim, a Hyeyoung Lee, d Sang-Nae Cho, a,#

Department of Microbiology and Institute of Immunology and Immunological Diseases, Brain Korea 21 Plus Project for the Medical Sciences, Yonsei University College of Medicine, Seoul, Republic of Korea a; Division of Pulmonology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea b; National Mokpo Hospital, Mokpo, Jeonnam, Republic of Korea c; Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University, Wonju, Gangwon, Republic of Korea d

Running Head: IgG responses to M. tb antigens in active TB and LTBI

#Address correspondence to Prof. Sang-Nae Cho, raycho@yuhs.ac
This study aimed to evaluate the serodiagnostic potential of immunoglobulin G (IgG) responses to *Mycobacterium tuberculosis* (*M. tb*) antigens in pulmonary tuberculosis (TB) patients, recent TB contacts with latent TB infection (LTBI), and healthy subjects. Infections were assessed using tuberculin skin tests, QuantiFERON-TB Gold In-Tube tests, drug susceptibility testing, and molecular genotyping of clinical isolates, and serum IgG responses to selective *M. tb* antigens including the 38 kDa and 16 kDa antigens, lipoarabinomannan (LAM), and recombinant early secreted antigen target 6 kDa (ESAT-6) and culture filtrate protein 10 kDa (CFP-10) were determined. We found that serum IgG responses to all antigens could differentiate between active TB and LTBI, with LAM having the highest diagnostic value (AUC=0.7756, *P*<0.001). Recurrent TB cases showed significantly higher IgG responses to 38 kDa, CFP-10 (*P*<0.01), and LAM (*P*<0.05) than new cases, and male patients had higher levels of antigen-specific IgG, as compared with females (*P*<0.05). Conversely, drug resistance and patient body mass index did not affect IgG responses (*P*>0.05). LAM-specific IgG responses differentiated between AFB-smear positive and negative patients (*P*<0.01), whereas antigen-specific IgG responses did not vary with *M. tb* genotype (*P*>0.05). Significantly higher IgG responses to 38 kDa and 16 kDa were observed in AFB-smear negative patients, as compared with controls. These results suggest that assessment of serum IgG responses to selective purified *M. tb* antigens may help improve diagnosis of active TB, particularly for sputum-smear negative patients or recurrent cases, and these may also help to differentiate between active TB and LTBI.
INTRODUCTION

Tuberculosis (TB), an infectious disease caused by *Mycobacterium tuberculosis* (*M. tb*), remains a major global health problem and is a significant cause of morbidity and mortality worldwide (1). It is estimated that nearly one-third of the world’s population is latently infected with *M. tb* (2), and around 8.6 million new cases were reported to the World Health Organization (WHO) globally in 2012 (1). About 3.6% of new cases are caused by multidrug resistant strains (MDR), and levels of MDR-TB were found to be higher (~20%) in patients previously treated for TB (3). Notably, high risk of MDR and epidemic spread of TB in Asia is associated with *M. tb* Beijing strain (4-5).

Current TB diagnostics rely mostly on identification of *M. tb* clinical isolates by acid-fast bacillus (AFB) staining or culture (6). Although AFB-smear staining allows rapid detection of mycobacteria in clinical specimens, it has relatively low sensitivity, with a greater failure rate in children and immunocompromised groups, such as the elderly and patients with acquired immunodeficiency syndrome (6). The culture method is more sensitive than AFB staining, but it takes several weeks to obtain results and requires laboratory facilities that may be unavailable in resource-limited settings (6). Immunological approaches, such as the tuberculin skin test (TST) and IFN-γ release assay (IGRA), have also been developed for detecting latent TB infection (LTBI). The IGRA has higher specificity than TST due to the use of *M. tb* specific peptide antigens, such as early secreted antigen target 6 kDa (ESAT-6), culture filtrate protein 10 kDa (CFP-10), and TB7.7 (7-8). However, both TST and IGRA failed to discriminate between LTBI and active TB in areas with high burden of TB (9-10), indicating there is no gold standard for differential diagnosis between active TB and LTBI.

Development of a serodiagnostic method for TB diagnosis has garnered considerable interest, as these assays are both simple and cost-effective; however, efforts have been hampered by inconsistent results (11). Notably, while serodiagnosis of TB by combining immunoglobulin classes was suggested as a useful point-of-care test in South Africa (13), poor performance of commercial serological tests for diagnosing pulmonary TB was reported in India (12), and to date, no
commercial serodiagnostic tests have demonstrated acceptable sensitivity and specificity for routine laboratory use. In previously developed tests, these have varied depending on the recombinant antigens tested (14), and changes in antibody levels following successful anti-TB treatment also varied with different antigens (15-17). Inconsistent *M. tb* antigen-specific antibody titres were also found in populations with variable levels of *M. tb* exposure (18). Moreover, antibody responses were much stronger in sputum-smear positive TB than in sputum-smear negative TB (19-20). These reports indicate that when developing TB serodiagnostics, factors such as the antigens utilized, population variation, stage of infection, and bacillary load should be considered.

Based on the reports showing significantly higher sensitivities of the IgG test compared with the IgM, IgA or IgG/IgM tests in response to mycobacterial antigens (21-22), we aimed to evaluate IgG responses to five different *M. tb* antigens which are 38 kDa, 16 kDa, ESAT-6, CFP-10, and lipoarabinomannan (LAM) in sera of active TB patients, TB contacts with LTBI, and controls. We correlated antigen-specific IgG responses with infection state, TB recurrence, drug resistance, bacterial burden, *M. tb* genotype, and patient body mass index (BMI) and gender, in order to identify candidate antigens with clinical value for TB diagnosis and elucidate factors that may influence *M. tb*-specific IgG responses in TB patients.
MATERIALS AND METHODS

Enrolment of study subjects

In total, 159 pulmonary TB patients, 51 recent TB contacts, and 133 healthy subjects were recruited at two hospitals in South Korea. From February 2011 to December 2012, 73 TB patients (mean age: 46) were enrolled at Mokpo National Hospital, and from November 2010 to December 2013, 86 TB patients (mean age: 32), 51 asymptomatic TB contacts (mean age: 44), and 133 healthy subjects (mean age: 31) were enrolled at Severance Hospital (Fig. 1). Informed written consent was obtained from all participants for interviews and for diagnostic and immunological tests. Active pulmonary TB was diagnosed by confirmation of *M. tb* from sputum smear/culture and chest X-ray (7), and genotypes of infecting *M. tb* strains were confirmed by molecular genotyping (23) in 94 patients. LTBI and control groups were defined based on results of TSTs and QFT-IT tests (7-8). Among the 51 TB contacts, 26 showed positive IFN-**γ** responses in QFT-IT tests; double positive responses in TSTs (≥10 mm) and QFT-IT tests were observed in 19 of the 26 TB contacts while 7 of the 26 TB contacts had negative TST results (<10 mm). Control group consisted of 54 individuals with double negative responses in TSTs (<10 mm) and QFT-IT tests among the 133 healthy individuals who had never contacted with TB patients. Subjects taking immunosuppressants, or those with cancer, diabetes, or renal disease were excluded. Our final study population consisted of 94 TB patients, 26 contacts with LTBI, and 54 healthy controls (Fig.1).

Ethical approval was granted by Mokpo National Hospital Ethics Review Committee (approval number 2010-001) and the Severance Hospital Ethics Review Committee (approval number 4-2010-0213).

TST
An intradermal injection of Tuberculin Purified Protein Derivative (0.1 mL of RT-23, Statens Serum Institute, Copenhagen, Denmark) was given to all participants. Induration size was determined at 48 and 72 hours, and measurements ≥10 mm were classified as positive.

**Preparation of blood samples**

Serum samples were separated by centrifugation from 4 mL of blood (VACUETTE® serum tube, Greiner Bio-One GmbH, Frickenhausen, Germany). For QFT-IT tests, a total of 3 mL blood was collected directly into each of three QFT-IT tubes [Nil, *M. tb* Ag tube (ESAT-6, CFP-10, and TB7.7 peptide antigens), and mitogen (PHA), Cellestis, CA, USA]. Plasma was harvested after incubation at 37°C for 24 h, and IFN-γ enzyme-linked immunosorbent assays (ELISAs) were performed according to manufacturer’s protocol (QuantiFERON-TB Gold, Cellestis).

**Molecular genotyping of M. tb**

*M. tb* genotypes were determined by MTB/Beijing genotyping® (Optipham-M&D, Wonju, South Korea) based on large-sequence polymorphism analysis (23). Briefly, genomic DNA was extracted by boiling a mycobacterial suspension scraped from Lowenstein-Jensen media slants (Becton Dickinson and Company, MD, USA) in 400 µl buffer (10 mMTris-HCl, pH 8.0, 1 mM EDTA). DNA served as a template for gene amplification using Veriti® 96-Well Fast Thermal Cycler (Applied Biosystems®, Life technologies, CA, USA), and products were analysed using agarose gel electrophoresis.

**Purification of recombinant protein antigens**

The 38 kDa and 16 kDa antigens were provided by Standardia Diagnostics, Inc. (Suwon, South Korea), and LAM was obtained from the Mycobacteria Research Laboratory, Colorado State University (Fort Collins, Colorado, USA). Vector construction for expression of recombinant ESAT-6 and CFP-10 was performed using the *NdeI* and *BamHI* (New England Biolabs, MA, USA).
sites of pET11a_KB, and genes were amplified from *M. tb* H37Rv genomic DNA. Plasmids encoding ESAT-6 and CFP-10 were transformed into *E. coli* BL21(DE3) for protein overexpression, and recombinant proteins were purified using Ni-NTA resin (Qiagen, CA, USA) and fast protein liquid chromatography (ÄKTA FPLC, GE Healthcare Life Sciences, PA, USA) with a MonoQ anion exchange column (GE Healthcare Life Sciences).

Measurement of IgG responses to *M. tb* antigens

*M. tb* antigens were coated in 96-well microplates (Corning Inc., NY, USA) at 2 μg/mL (38 kDa, 16 kDa, ESAT-6, CFP-10) or 0.1 μg/mL (LAM) in 0.5M carbonate-bicarbonate buffer overnight at 4°C. Plates were washed three times in phosphate-buffered saline (PBS) supplemented with 0.05% tween20 (PBST) and blocked with PBST containing 5% normal goat serum (PBST-NGS) at 37°C for 1 h. Blocked plates were incubated with human serum samples (1:300 dilution in PBST-NGS) at 37°C for 2 h, washed again with TBST, and incubated with peroxidase-conjugated anti-human IgG antibody (1:10,000 dilution in PBST-NGS, Calbiochem, CA, USA) at 37°C for 1 h. Plates were washed again with TBST, and tetramethylbenzidine (KPL, MD, USA) was added. The reaction was stopped with 2.5N H₂SO₄, and optical density (OD) was measured at 450 nm using the ELISA microplate reader (Molecular Devices, CA, USA).

Statistical analysis

Differential *M. tb* antigen-specific IgG responses in TB patients, contacts with LTBI, and healthy controls were analysed by Kruskal-Wallis and Dunn’s multiple comparison tests. IgG responses between groups based on TB recurrence, drug resistance, AFB staining, *M. tb* genotype, and patient BMI and gender were analysed by Mann-Whitney tests. Diagnostic values of IgG responses to *M. tb* antigens were examined by analysis of receiver operating characteristic (ROC) curves.
RESULTS

M. tb antigen-specific IgG responses in active TB, LTBI, and controls

In order to determine M. tb antigen-specific IgG responses according to the infection status, IgG responses were evaluated in active TB, LTBI and control groups. We found that active TB patients showed significantly higher IgG responses than controls to all antigens tested (P<0.001 or P<0.01, Fig. 2a). The area under the ROC curve (AUC) for 38 kDa-specific IgG responses was the highest among the five antigens (AUC=0.7695, P<0.001), followed by LAM and 16 kDa (Table 1). Sensitivity (73.4%) and specificity (70.4%) were also highest for 38 kDa-specific IgG responses (Table 1). Although ESAT-6- and CFP-10-specific IgG responses differed between active TB and controls (Fig.2a), the low AUCs (<0.7) and sensitivities (55.3% and 51.1%, respectively) of those responses did not provide diagnostic value (Table 1). Active TB and LTBI were differentiated by IgG responses to all antigens tested (P<0.01, Fig.2a), with the highest AUC (0.7756, P<0.001), sensitivity (67.0%), and specificity (80.8%) observed for LAM-specific responses (Table 1).

M. tb antigen-specific IgG responses based on history of TB patients

Of 94 active TB patients, 58 were newly diagnosed, and 36 previously had TB. These 36 patients, defined as recurrent cases, included individuals with relapsed TB after successful treatment and those whose initial treatment failed, either due to self-stop or drug resistance. The IgG responses to all antigens tested were significantly higher in recurrent cases than in controls (Fig.2b), and AUC, sensitivity, and specificity values were higher for recurrent cases than for new cases vs. controls (Table 1). In particular, almost a two-fold difference was found in sensitivity of CFP-10-specific IgG responses between recurrent (72.2%) and new cases (36.2%) (Table 1). The IgG responses to 38 kDa, 16 kDa, and LAM also differentiated between new cases and controls (Fig.2b).

Effects of drug susceptibility and BMI on IgG responses
A total of 23 patients were classified with drug resistant *M. tb*, including two extensively drug-resistant (XDR) and three MDR patients out of 88 tested for drug susceptibility. IgG responses to all antigens were not significantly different in these patients, as compared to those with drug-sensitive *M. tb* (*P*>0.05, data not shown). The *M. tb* antigen-specific IgG responses also did not vary in 24 patients with BMIs<18.5 and the 64 patients with BMIs in the normal range (18.5<BMI<25) (data not shown).

**Association between antigen-specific IgG responses and *M. tb* isolates**

*M. tb* antigen-specific IgG responses were analysed based on results of AFB-smear staining and *M. tb* genotyping. In response to 38 kDa, 16 kDa, ESAT-6, and CFP-10, we observed no significant differences depending on AFB-smear staining results in 91 TB patients tested (Fig. 3a). However, AFB-smear positive patients showed significantly higher IgG responses to LAM, as compared to those with negative results (*P*<0.01, Fig. 3a); analysis of the ROC curve in AFB-smear positive (AUC=0.8909, *P*<0.001) and negative patients (AUC=0.6857, *P*<0.001) confirmed these results. Conversely, 38 kDa- and 16 kDa-specific IgG responses showed good diagnostic values (AUC>0.7, *P*<0.001) in sputum-smear negative patients. Genotyping revealed that Beijing strains accounted for about 81% (76/94) of the isolates in our study; however, antigen-specific IgG responses did not differ according to strain genotype (*P*>0.05, Fig. 3b).

**Influence of gender on IgG responses**

We found that antigen-specific IgG responses were significantly higher in male (n=64) than female (n=30) patients in response to all antigens, with the exception of ESAT-6 (Fig. 4). The differences were particularly significant for 38 kDa- and LAM-specific IgG responses (*P*<0.001). It should be noted that the percentage of recurrent cases, drug resistance, and positive AFB-smear test results were all more than 2-fold higher in male patients, as compared with female patients, while mean age, BMI, and proportions of *M. tb* genotypes were similar among the two groups (Table 2).
DISCUSSION

In this study, we found that *M. tb* antigen-specific IgG responses are affected by infection state (active vs. LTBI), TB recurrence, bacterial burden, and gender; whereas age, BMI, and *M. tb* genotype had no effect. While considerable effort has focused on identifying biomarkers for differential diagnosis of LTBI and active TB (9, 24), we observed that LAM-specific IgG responses reliably differentiated these, suggesting this might be an informative marker for clinical diagnosis. LAM is a major cell wall component that contributes to *M. tb* pathogenicity by arresting host phagosomal maturation and blocking T cell proliferation (25). We found that only LAM-specific IgG responses differed between AFB-smear positive and negative TB patients (*P*<0.01), suggesting these are more associated with bacillary load, as compared with other antigens tested.

Many studies have focused on identifying novel antigens to improve sensitivity and specificity of current TB diagnostics, particularly for sputum-smear negative patients or those incapable of producing sputum. In our study, approximately 60.4% of 94 culture-confirmed TB patients failed to identify *M. tb* by AFB-smear test. We observed that IgG responses to 38 kDa did not vary based on sputum-smear results; however, both smear-positive and negative patients showed significantly higher levels of IgG than controls. The 38 kDa antigen is a surface-exposed lipoprotein, which has been previously been exploited for TB serodiagnosis (26). Sensitivity and specificity of serodiagnostic tests based on this antigen have been reported to range from 40-89% and 44-100%, respectively, depending on study population and test laboratory (26). We observed approximately 70% sensitivity and specificity, with a good diagnostic value (AUC>0.7, *P*<0.001), for the 38 kDa antigen in both AFB-smear positive and negative patients. These data indicate that measuring IgG response to 38 kDa may facilitate early diagnosis of TB, particularly in sputum-smear negative patients or those unable to produce sputum. Recurrent disease with a poor prognosis has also been associated with high levels of anti-38 kDa antibody (19), which corroborates our findings showing high diagnostic value (AUC=0.8593, *P*<0.001) and enhanced sensitivity and specificity (81% and
78%, respectively) of 38 kDa in recurrent cases. The proportion of patients infected with Beijing strain was about 4-times higher than those infected with non-Beijing strains (81% vs. 19.1%); however, this did not correlate with antigen-specific IgG responses, perhaps due to the limited number of XDR/MDR patients in our drug resistant cohort. Gender appeared to affect antigen-specific IgG responses, although this result is likely due, at least somewhat, to the differential frequency and severity of TB in male and female patients. TB rates are approximately twice as high in men as in women, suggesting men are more susceptible to TB (1), although the biological basis for this discrepancy remains unclear. A higher frequency of exposure to TB in men and other gender specific factors might also influence antigen-specific antibody responses. Sex steroid hormones have been suggested to play a protective role against mycobacterial infection (27-28), but their role remains to be elucidated. In conclusion, we found that a serodiagnostic test for TB using 38 kDa and LAM antigens may be developed as a rapid and economic point-of-care test in resource limited settings, particularly for early diagnosis in sputum-smear negative cases and recurrent cases, and for the differential diagnosis between active TB and LTBI. However, the sensitivities and specificities of the responses should be enhanced for clinical use of diagnosis between active TB and LTBI. Further studies should focus on improving the sensitivity and specificity of serodiagnostic tests by selecting epitopes to enhance antibody responses and by assessing combinations of antigens for possible synergistic effects.
ACKNOWLEDGMENTS

We thank all of the study participants and staffs at Mokpo National Hospital and Severance Hospital in South Korea for their assistance.

This study was funded by the Ministry for Health, Welfare, and Family Affairs, Republic of Korea (Korean Health Technology R&D Project: A101750). The funding sources had no role in the study process, including study design, sample collection, analysis, and interpretation of the results.

CONFLICTS OF INTERESTS

The authors declare no conflicts of interests.
REFERENCES


FIGURE LEGENDS

Figure 1. Enrolment of study participants. In total, 159 active TB patients, 51 TB contacts, and 133 healthy subjects were recruited from Mokpo National Hospital (MNH) and from Severance Hospital (SH). Of these, the genotypes of infecting M. tb strains were confirmed in 94 TB patients. Based on QFT-IT test and TST, 26 TB contacts were defined as individuals with LTBI and 54 normal healthy controls were identified.

Figure 2. Antigen-specific IgG responses according to infection state and TB recurrence. (a) TB patients (n=94) had significantly higher IgG responses to all antigens tested, as compared to individuals with LTBI (n=26) and controls (n=54), whereas, there were no significant differences in IgG responses between individuals with LTBI and controls. (b) M. tb antigen-specific IgG responses were compared between recurrent TB (n=36) and new cases (n=58). In response to 38 kDa, CFP-10, and LAM, recurrent cases showed significantly higher IgG responses, as compared to new cases. The IgG responses to 38 kDa and LAM also differed between new cases and controls; whereas, ESAT-6 and CFP-10 did not differentiate between these groups. Median levels of IgG responses are indicated with horizontal bars in red (*P<0.05, **P<0.01, ***P<0.001).

Figure 3. Antigen-specific IgG responses depending on identification of M. tb by AFB-smear tests and M. tb genotypes. (a) Median IgG response to LAM was significantly higher in patients who showed positive AFB-smear test results (AFB+ve, n=36) than those with negative results (AFB-ve, n=55). However, all AFB-smear negative patients showed significantly higher IgG responses than controls in response to all antigens tested. (b) The majority of patients (81%) were infected with the M. tb Beijing strain, but genotype did not affect antigen-specific IgG responses (n=76 for Beijing strain, n=18 for non-Beijing strain). Median responses are indicated with horizontal bars in red (*P<0.05, **P<0.01, ***P<0.001).
Figure 4. Effect of gender on antigen-specific IgG responses in TB patients. *M. tb* antigen-specific IgG responses were compared between male (n=64) and female (n=30) TB patients. In response to all antigens, with the exception of ESAT-6, male patients showed significantly higher IgG responses. Median responses are indicated with horizontal bars in red (*P<0.05, **P<0.01, ***P<0.001).
Table 1. Analysis of ROC curves for antigen-specific IgG responses in different patient groups.

<table>
<thead>
<tr>
<th></th>
<th>AUC (p value)</th>
<th>% sensitivity</th>
<th>% specificity</th>
<th>cut-off (OD)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>active TB vs control</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38 kDa</td>
<td>0.7695 (&lt; 0.001)</td>
<td>73.4</td>
<td>70.4</td>
<td>&gt; 0.015</td>
</tr>
<tr>
<td>16 kDa</td>
<td>0.7535 (&lt; 0.001)</td>
<td>71.3</td>
<td>70.4</td>
<td>&gt; 0.010</td>
</tr>
<tr>
<td>ESAT-6</td>
<td>0.6544 (&lt; 0.01)</td>
<td>55.3</td>
<td>70.4</td>
<td>&gt; 0.021</td>
</tr>
<tr>
<td>CFP-10</td>
<td>0.6643 (&lt; 0.001)</td>
<td>51.1</td>
<td>70.4</td>
<td>&gt; 0.024</td>
</tr>
<tr>
<td>LAM</td>
<td>0.7655 (&lt; 0.001)</td>
<td>68.1</td>
<td>70.4</td>
<td>&gt; 0.189</td>
</tr>
<tr>
<td><strong>active TB vs LTBI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38 kDa</td>
<td>0.7064 (&lt; 0.01)</td>
<td>58.5</td>
<td>73.1</td>
<td>&gt; 0.027</td>
</tr>
<tr>
<td>16 kDa</td>
<td>0.7535 (&lt; 0.001)</td>
<td>64.9</td>
<td>73.1</td>
<td>&gt; 0.012</td>
</tr>
<tr>
<td>ESAT-6</td>
<td>0.6966 (&lt; 0.01)</td>
<td>55.3</td>
<td>73.1</td>
<td>&gt; 0.021</td>
</tr>
<tr>
<td>CFP-10</td>
<td>0.7398 (&lt; 0.001)</td>
<td>64.9</td>
<td>76.9</td>
<td>&gt; 0.019</td>
</tr>
<tr>
<td>LAM</td>
<td>0.7756 (&lt; 0.001)</td>
<td>67.0</td>
<td>80.8</td>
<td>&gt; 0.210</td>
</tr>
<tr>
<td><strong>recurrent case vs control</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38 kDa</td>
<td>0.8593 (&lt; 0.001)</td>
<td>80.6</td>
<td>77.8</td>
<td>&gt; 0.019</td>
</tr>
<tr>
<td>16 kDa</td>
<td>0.8027 (&lt; 0.001)</td>
<td>75.0</td>
<td>77.8</td>
<td>&gt; 0.012</td>
</tr>
<tr>
<td>ESAT-6</td>
<td>0.6965 (&lt; 0.01)</td>
<td>63.9</td>
<td>74.1</td>
<td>&gt; 0.024</td>
</tr>
<tr>
<td>CFP-10</td>
<td>0.7744 (&lt; 0.001)</td>
<td>72.2</td>
<td>72.2</td>
<td>&gt; 0.025</td>
</tr>
<tr>
<td>LAM</td>
<td>0.8498 (&lt; 0.001)</td>
<td>72.2</td>
<td>74.1</td>
<td>&gt; 0.237</td>
</tr>
<tr>
<td><strong>new case vs control</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38 kDa</td>
<td>0.7138 (&lt; 0.001)</td>
<td>67.2</td>
<td>70.4</td>
<td>&gt; 0.015</td>
</tr>
<tr>
<td>16 kDa</td>
<td>0.7230 (&lt; 0.001)</td>
<td>67.2</td>
<td>70.4</td>
<td>&gt; 0.010</td>
</tr>
<tr>
<td>ESAT-6</td>
<td>0.6282 (&lt; 0.05)</td>
<td>50.0</td>
<td>70.4</td>
<td>&gt; 0.021</td>
</tr>
<tr>
<td>CFP-10</td>
<td>0.5959 (&lt; 0.05)</td>
<td>36.2</td>
<td>70.4</td>
<td>&gt; 0.024</td>
</tr>
<tr>
<td>LAM</td>
<td>0.7131 (&lt; 0.001)</td>
<td>65.5</td>
<td>70.4</td>
<td>&gt; 0.189</td>
</tr>
</tbody>
</table>

AUC, sensitivity, specificity, and cut-off values were calculated by analysis of the ROC curves between the different groups tested. Serum IgG responses to 38 kDa, 16 kDa, and LAM showed higher sensitivities and specificities to diagnose active TB or LTBI, as compared to ESAT-6 and CFP-10- specific IgG responses. The AUC, sensitivity, and specificity were higher in recurrent cases than in new cases.
Table 2. Characteristics of male and female TB patients. Male patients had higher percentages of TB recurrence, drug resistance, and positive AFB-smear test (% AFB-smear+ve) results, as compared with female patients. However, age and BMI were not significantly different between the groups. *Fold difference was calculated by dividing the values of male patients by those of female patients.

<table>
<thead>
<tr>
<th></th>
<th>male (n=64)</th>
<th>female (n=30)</th>
<th>fold difference*</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean age</td>
<td>43</td>
<td>32</td>
<td>1.3</td>
</tr>
<tr>
<td>mean BMI</td>
<td>20</td>
<td>19</td>
<td>1.0</td>
</tr>
<tr>
<td>% recurrence in TB</td>
<td>47</td>
<td>20</td>
<td>2.4</td>
</tr>
<tr>
<td>% drug resistance</td>
<td>32</td>
<td>14</td>
<td>2.3</td>
</tr>
<tr>
<td>% AFB-smear+ve</td>
<td>54</td>
<td>10</td>
<td>5.4</td>
</tr>
<tr>
<td>% Beijing strain</td>
<td>81</td>
<td>80</td>
<td>1.0</td>
</tr>
</tbody>
</table>